Liver Cancer Clinical Trials in District of Columbia

45 recruiting studies across 1 city

Browse by City

All Trials in District of Columbia

Phase

Trial	Phase	Sponsor	Dist.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis	Phase 2	Genentech, Inc.	<1 mi
FOG-001 in Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Parabilis Medicines, Inc.	<1 mi
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors	Phase 2	SWOG Cancer Research Network	<1 mi
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI	N/A	VA Office of Research and Development	<1 mi
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Phase 1/2	Hoffmann-La Roche	<1 mi
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	Phase 1/2	Tvardi Therapeutics, Incorporated	<1 mi
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer	Phase 2	AstraZeneca	<1 mi
Cancer Experience Registry (CER) for Cancer Patients and Caregivers	—	Cancer Support Community, Research and Training Institute, Philadelphia	<1 mi
Evaluating Novel Therapies in ctDNA Positive GI Cancers	Phase 3	Georgetown University	<1 mi
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/2	Children's Oncology Group	<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy	Phase 3	Pierre Fabre Medicament	<1 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	Phase 3	AstraZeneca	4 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	—	Massive Bio, Inc.	6 mi
Role of Genetic Factors in the Development of Lung Disease	—	National Heart, Lung, and Blood Institute (NHLBI)	6 mi
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors	Phase 2	DualityBio Inc.	6 mi
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies	Phase 1	National Cancer Institute (NCI)	6 mi
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies	—	National Cancer Institute (NCI)	6 mi
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection	Phase 2	National Cancer Institute (NCI)	6 mi
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	Phase 1	National Cancer Institute (NCI)	6 mi
Collection of Blood From Patients With Cancer	—	National Cancer Institute (NCI)	6 mi
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma	Phase 2	National Cancer Institute (NCI)	6 mi
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	Phase 3	NRG Oncology	7 mi
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer	Phase 2/3	Inova Health Care Services	7 mi
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)	Phase 2	Inova Health Care Services	7 mi
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors	Phase 1	Pliant Therapeutics, Inc.	15 mi
The Vanguard Study: Testing a New Way to Screen for Cancer	N/A	National Cancer Institute (NCI)	15 mi
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors	Phase 1/2	Tango Therapeutics, Inc.	15 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	15 mi
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	15 mi
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer	Phase 2	AstraZeneca	15 mi
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors	Phase 1	Conjupro Biotherapeutics, Inc.	15 mi
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)	Phase 2	Daiichi Sankyo	15 mi
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors	Phase 1	Angiex, Inc.	15 mi
Integrated Cancer Repository for Cancer Research	—	University of Nebraska	34 mi
Multi-analyte Blood Test Clinical Trial	—	Helio Genomics	35 mi
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours	Phase 1/2	AstraZeneca	35 mi
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC	Phase 1/2	RayzeBio, Inc.	35 mi
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma	Phase 1	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	35 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors	Phase 1	Exelixis	35 mi
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations	Phase 1	Tyra Biosciences, Inc	35 mi
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery	Phase 2	National Cancer Institute (NCI)	35 mi
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	Phase 2	Replimune, Inc.	35 mi
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment	Phase 1	Gilead Sciences	35 mi
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies	—	Elephas	40 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.